🔗 Share this article

While the US proceeds with historic adjustments to its immunization recommendations, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by questioning COVID-19 vaccinations in the global health crisis and has zeroed in on potential fatalities following Covid immunization in her recent position at the FDA.

Scheduled Shifts to Childhood Vaccine Schedule

Agency leaders planned to reveal major revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s national calendar, according to reports – a significant shift that would place the US out of alignment with many the world with no evidence for benefit. This reveal has been delayed until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to present at the event. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this calendar year.

A New Direction at the Agency

The acting appointment may indicate a closer partnership between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon dismantling long-standing immunizations at the FDA.

The new acting director has repeatedly called for discontinuing specific pediatric vaccine recommendations in the US so as to align more like Denmark, a society with universal health coverage and a population about the size of the state of Wisconsin.

To date statements, she has kept her attention on vaccines – typically the domain of Prasad, director of the FDA’s CBER – rather than medication approval.

Questions Over Qualifications

Dr. Høeg has no obvious experience in drug development, regulation or management, which has been typical for past leaders of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, stated Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in managing a large organization. She lacks background in industry regulation.”

Previous heads of CBER would “understand legal statutes and the research of medication creation”, commented Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that previous people who led CBER have had.”

CDER has an vast portfolio at the agency, Woodcock emphasized.

“Everybody just focuses on the novel medication approvals, but the off-patent medication office clears numerous generic medications. There is also a biosimilars division, OTC medication office and so forth, and every single one have to be managed,” she said. “The area you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a significant management aspect to the role, which manages in excess of 5,000 personnel. “It’s a massive leadership role, if you do it right,” the former official added.

Response and Controversial Policies

Regarding questions about Dr. Høeg's fitness for the role and whether this selection represents increased cooperation among FDA leaders on immunizations, a press secretary stated that the “inquiries stem from inaccurate premises”.

“This background matches the responsibilities of her role,” the official explained, noting the months Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s recently launched priority voucher program, a contentious rapid medication authorization process that apparently worried her former heads. “By what process are these therapies being selected for this voucher program? Who is making the calls?” Dr. Howard asked. “There is a lot of confidentiality going on at the regulatory body right now.”

Overall, he stated, “the agency appears to be shifting towards laxer rules of pharmaceuticals, except for vaccines.”

Documented Track Record on Immunizations

Regarding vaccines, Høeg has a more documented, if concerning, past, Howard observe. She released a study using unverified crowd-sourced reports to assess the frequency of myocarditis after COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are riskier than they are.

Part of her “desired changes” for the incoming government featured revising rules for novel immunizations and ending “unnecessary” vaccines, she stated post-election on a audio program. At the agency, Dr. Høeg has reportedly proposed barring young men from getting Covid vaccines.

“She’s an thorough dogmatist who begins with her beliefs and tailors the evidence to accommodate the science in a very deceptive, dishonest fashion,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow skeptics, {like|